Mechanism of Action: Ophthalmology Literature
The general mechanisms of photobiomodulation, energy, perfusion and reduced inflammation, described in the basic-science literature, take on specific meaning in the eye. The ophthalmology literature describes how these effects act on the ocular surface and the retina, and it is the bridge between the bench science and the clinical evidence.
On the ocular surface and eyelids
At the front of the eye, the relevant effects are on inflammation and gland function. By calming inflammatory signalling and supporting the meibomian glands, photobiomodulation acts on the drivers of evaporative dry eye and meibomian gland dysfunction. This is the mechanistic basis for the improvements in tear-film stability and gland function seen in the clinical trials, and for the recognition of LM™ LLLT across all three driver groups in TFOS DEWS III (2025, American Journal of Ophthalmology), the tear film, the eyelids and the ocular surface.
In the retina
In the posterior segment, the same biology is relevant to retinal cell health. Photobiomodulation has been associated with restored mitochondrial function and ATP production in photoreceptors and with reduced oxidative stress, mechanisms directly pertinent to the cellular stress that characterises dry AMD. Yellow wavelengths have additionally been described as inhibiting VEGF expression, the signal that drives abnormal blood-vessel growth.
The perfusion signal in AMD
A particularly notable finding in the ophthalmology literature concerns the choroidal circulation. In intermediate AMD, photobiomodulation was associated with enhanced choriocapillaris perfusion and outer retinal remodelling, alongside functional improvement and drusen reduction (Viggiano et al., 2025, Eye). This links the nitric-oxide and perfusion mechanism from basic science to a measurable change in the diseased retina. Randomised controlled data subsequently showed that PBM reduces drusen burden and improves visual acuity in early and intermediate dAMD over 12 months, consistent with this mitochondrial and anti-inflammatory mechanism (Iovino et al., 2026, British Journal of Ophthalmology).
Why it matters
A defined biological mechanism is what separates a credible therapy from an empirical one. The ophthalmology mechanism-of-action literature explains why photobiomodulation produces the effects documented in the publication library and the clinical trials, across both segments of the eye.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.